Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. Foghorn will now focus on its own drug programs and reduce its workforce by about 40% to extend its cash runway into late 2029. The stock dropped sharply on the news amid high trading volume, reflecting investor concern over the strategic shift and pipeline changes.
Following the news of Foghorn Therapeutics' strategic shift and workforce reduction, Eli Lilly's stock shows a slight decline. On Pluang, as of Oct 02, 2026 02:41 WIB, Eli Lilly (LLY) trades at USD 1,155.14 with a 1-day change of -0.17%. The stock's market cap stands at $1.03 trillion, and the platform records a nearly balanced order activity with 52% Sell and 48% Buy.
Eli Lilly's Foundayo (orforglipron) showed in post-hoc analyses of the ATTAIN-1 trial a significant reduction in predicted 10-year risks of type 2 diabetes and cardiovascular disease among adults with obesity or overweight with related health issues....
The Phase 3 ACHIEVE-4 trial found that Foundayo (orforglipron) reduced the risk of major cardiovascular events by 16% and cardiovascular death by 53% compared to insulin glargine in adults with type 2 diabetes and obesity. It also improved blood suga...
EBGLYSS (lebrikizumab-lbkz) monotherapy achieved its primary endpoint in the Phase 3b ADtouch trial, with over half of patients showing clear or almost clear skin on hands and feet by Week 16. The treatment also provided significant itch and pain rel...
Novo Nordisk's analysis of real-world data shows that patients who switched from obesity injections like Wegovy or Lilly's Zepbound to Novo's new Wegovy pill continued to lose weight, shedding about 4% of their body weight on average after three mont...
Eli Lilly is growing faster than any other large drugmaker, driven by strong sales of Mounjaro and new FDA approvals for cardiovascular risk reduction and insulin products. The company plans to seek approval for retatrutide in early 2027, a drug show...
